These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 28775168)

  • 1. JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.
    Ye J; Li TS; Xu G; Zhao YM; Zhang NP; Fan J; Wu J
    Cancer Res; 2017 Oct; 77(19):5287-5300. PubMed ID: 28775168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
    Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
    J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JCAD, a Gene at the 10p11 Coronary Artery Disease Locus, Regulates Hippo Signaling in Endothelial Cells.
    Jones PD; Kaiser MA; Ghaderi Najafabadi M; Koplev S; Zhao Y; Douglas G; Kyriakou T; Andrews S; Rajmohan R; Watkins H; Channon KM; Ye S; Yang X; Björkegren JLM; Samani NJ; Webb TR
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1711-1722. PubMed ID: 29794114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2.
    Han LL; Yin XR; Zhang SQ
    Int J Oncol; 2018 Dec; 53(6):2433-2444. PubMed ID: 30272278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JCAD deficiency delayed liver regenerative repair through the Hippo-YAP signalling pathway.
    Zhang L; Yang YY; Xie L; Zhou Y; Zhong Z; Ding J; Wang ZH; Wang YL; Liu XP; Yu FX; Wu J
    Clin Transl Med; 2024 Mar; 14(3):e1630. PubMed ID: 38509842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
    Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
    Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
    Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
    Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.
    Guo C; Wang X; Liang L
    Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
    Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
    J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
    Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
    [No Abstract]   [Full Text] [Related]  

  • 13. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
    Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101348. PubMed ID: 38697356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
    Ahn EY; Kim JS; Kim GJ; Park YN
    Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A FUS-LATS1/2 Axis Inhibits Hepatocellular Carcinoma Progression via Activating Hippo Pathway.
    Bao L; Yuan L; Li P; Bu Q; Guo A; Zhang H; Cui N; Liu B
    Cell Physiol Biochem; 2018; 50(2):437-451. PubMed ID: 30308519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
    Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
    Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.
    Myojin Y; Hikita H; Sugiyama M; Sasaki Y; Fukumoto K; Sakane S; Makino Y; Takemura N; Yamada R; Shigekawa M; Kodama T; Sakamori R; Kobayashi S; Tatsumi T; Suemizu H; Eguchi H; Kokudo N; Mizokami M; Takehara T
    Gastroenterology; 2021 Apr; 160(5):1741-1754.e16. PubMed ID: 33346004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
    Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
    Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Cell Death Pathway in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocarcinogenesis Is Associated with Histone H4 lysine 16 Deacetylation.
    de Conti A; Dreval K; Tryndyak V; Orisakwe OE; Ross SA; Beland FA; Pogribny IP
    Mol Cancer Res; 2017 Sep; 15(9):1163-1172. PubMed ID: 28512251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.